X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/bridge-biotherapeutics-launches-a-research-collaboration-with-emory-university-school-of-medicine-to-explore-combination-therapy-of-bbt-877-for-krasp53-mutant-nsclc-patients-resistant-to-anti-pd-1-blockade-302098969.html
https://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-a-research-collaboration-with-the-university-of-colorado-school-of-medicine-to-explore-potential-of-bbt-877-for-immuno-oncology-302098937.html
https://www.globenewswire.com//news-release/2023/12/14/2796008/0/en/GPCR-Therapeutics-Announces-Out-Licensing-Agreement-with-Bridge-Biotherapeutics-in-Idiopathic-Pulmonary-Fibrosis.html
https://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-initiation-of-phase-12-clinical-trial-of-bbt-207-in-egfr-mutant-nsclc-301971198.html
https://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-positive-recommendation-from-the-independent-data-monitoring-committee-of-the-bbt-877-phase-2a-study-in-idiopathic-pulmonary-fibrosis-301966925.html
https://www.prnewswire.com/news-releases/bridge-biotherapeutics-releases-updated-preclinical-data-for-bbt-207-at-the-aacr-annual-meeting-301801060.html
https://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-first-patient-dosed-in-its-phase-2a-clinical-trial-of-bbt-877-a-potent-autotaxin-inhibitor-for-the-treatment-of-idiopathic-pulmonary-fibrosis-301795588.html
https://www.prnewswire.com/news-releases/bridge-biotherapeutics-to-present-updated-preclinical-data-of-bbt-207-at-the-aacr-2023-annual-meeting-301772683.html
https://www.fiercebiotech.com/biotech/bridge-holds-firm-despite-placebo-beating-drug-midphase-ulcerative-colitis-trial
https://endpts.com/bridge-biotherapeutics-ulcerative-colitis-drug-fails-phase-ii-trial-biotech-plans-to-push-forward/
Market Place
Share 
